MacroGenics (MGNX) Competitors $1.69 -0.06 (-3.43%) Closing price 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.59%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. UPXI, KRRO, AUTL, ATXS, EOLS, ALMS, ETHZ, LRMR, ACIU, and FDMTShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Upexi (UPXI), Korro Bio (KRRO), Autolus Therapeutics (AUTL), Astria Therapeutics (ATXS), Evolus (EOLS), Alumis (ALMS), Flag Ship Acquisition (ETHZ), Larimar Therapeutics (LRMR), AC Immune (ACIU), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Its Competitors Upexi Korro Bio Autolus Therapeutics Astria Therapeutics Evolus Alumis Flag Ship Acquisition Larimar Therapeutics AC Immune 4D Molecular Therapeutics Upexi (NASDAQ:UPXI) and MacroGenics (NASDAQ:MGNX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Which has preferable earnings and valuation, UPXI or MGNX? Upexi has higher earnings, but lower revenue than MacroGenics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpexi$15.81M23.65-$13.68MN/AN/AMacroGenics$149.96M0.71-$66.97M-$0.57-2.96 Which has more volatility & risk, UPXI or MGNX? Upexi has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Do analysts recommend UPXI or MGNX? Upexi currently has a consensus target price of $15.50, suggesting a potential upside of 144.09%. MacroGenics has a consensus target price of $3.60, suggesting a potential upside of 113.02%. Given Upexi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Upexi is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upexi 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67MacroGenics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.29 Is UPXI or MGNX more profitable? MacroGenics has a net margin of -21.99% compared to Upexi's net margin of -86.54%. MacroGenics' return on equity of -40.24% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Upexi-86.54% -54.33% -31.28% MacroGenics -21.99%-40.24%-14.62% Do insiders and institutionals hold more shares of UPXI or MGNX? 5.7% of Upexi shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 4.4% of Upexi shares are held by insiders. Comparatively, 13.0% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to UPXI or MGNX? In the previous week, MacroGenics had 1 more articles in the media than Upexi. MarketBeat recorded 5 mentions for MacroGenics and 4 mentions for Upexi. Upexi's average media sentiment score of 1.46 beat MacroGenics' score of 0.77 indicating that Upexi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMacroGenics beats Upexi on 8 of the 13 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.61M$10.76B$6.11B$10.63BDividend YieldN/A1.88%5.66%4.71%P/E Ratio-2.9620.2785.2726.57Price / Sales0.7130.81612.79132.68Price / CashN/A25.5838.5062.09Price / Book0.913.3712.726.53Net Income-$66.97M$208.83M$3.30B$275.96M7 Day Performance-5.06%-2.89%1.05%-1.40%1 Month Performance-1.74%-0.06%7.56%5.16%1 Year Performance-54.81%-6.37%79.69%31.55% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics4.3842 of 5 stars$1.69-3.4%$3.60+113.0%-52.1%$110.61M$149.96M-2.96430News CoverageAnalyst ForecastUPXIUpexi2.6307 of 5 stars$7.70+3.5%$15.50+101.3%+184.2%$438.13M$15.81M0.00130Positive NewsKRROKorro Bio1.9823 of 5 stars$43.70-5.5%$86.83+98.7%+31.2%$434.05M$6.28M-4.4870News CoveragePositive NewsAUTLAutolus Therapeutics3.3895 of 5 stars$1.56-3.1%$9.12+484.6%-55.8%$428.49M$29.93M-1.86330News CoverageAnalyst ForecastATXSAstria Therapeutics2.4964 of 5 stars$7.69+2.3%$29.50+283.6%-23.1%$424.39MN/A-3.8330Analyst ForecastEOLSEvolus3.9757 of 5 stars$6.43-1.1%$21.25+230.5%-62.9%$420.45M$277.94M-6.56170News CoverageAnalyst RevisionALMSAlumis3.3528 of 5 stars$4.12+2.5%$20.17+389.5%-56.8%$418.34MN/A0.00N/AAnalyst ForecastETHZFlag Ship AcquisitionN/A$2.55+0.8%N/AN/A$416.01MN/A-0.177News CoverageAnalyst ForecastLRMRLarimar Therapeutics2.9012 of 5 stars$4.81-1.2%$16.71+247.5%-35.4%$403.13MN/A-3.0830Analyst ForecastGap DownACIUAC Immune2.0091 of 5 stars$3.54-11.3%$10.00+182.5%+2.7%$400.64M$28.92M-6.10140Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeFDMT4D Molecular Therapeutics2.4749 of 5 stars$8.40-1.8%$30.40+261.9%+6.2%$399.31M$40K-2.38120Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Upexi Alternatives Korro Bio Alternatives Autolus Therapeutics Alternatives Astria Therapeutics Alternatives Evolus Alternatives Alumis Alternatives Flag Ship Acquisition Alternatives Larimar Therapeutics Alternatives AC Immune Alternatives 4D Molecular Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTexit: The $1.4 trillion reason why tech is fleeing Cali for TexasThe state of Texas recently made a critical change to its laws… In a quest to become the AI data center cap...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
